Definition and research guide
This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.
Content available: 4 complete abstracts (888 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.
Definition
A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 3d ed, p1471)
Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.
Also known as: Basal Cell Epithelioma; Rodent Ulcer; Rodent Ulcers; Ulcers, Rodent; Carcinoma, Basal Cell; Pigmented Basal Cell Carcinoma.
Where it fits in the MeSH classification
- Broader topics
- Non-Melanoma Skin Neoplasms; Neoplasms, Basal Cell
- Narrower topics
- Basal Cell Nevus Syndrome
Research landscape
PubMed indexes 20,891 records tagged with the MeSH heading “Basal Cell Carcinoma” (counts retrieved 2026-10-29). 3,068 of them (14.7%) were published from 2020 onward, and the busiest period so far is through 1999 with 8,160 records.
Reviews account for 2,367 records (11.3%) and meta-analyses for 126. Randomized controlled trials number 279 (1.3%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.
Show the data
| Period | Records |
|---|---|
| through 1999 | 8,160 |
| 2000-2009 | 3,999 |
| 2010-2019 | 5,664 |
| 2020 onward | 3,068 |
Publication-type chart data
| Type | Records | Share |
|---|---|---|
| Reviews | 2,367 | 11.3% |
| Meta-analyses | 126 | 0.6% |
| Randomized controlled trials | 279 | 1.3% |
Method: PubMed query "Basal Cell Carcinoma"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-29.
Reading the evidence in cancer and oncology
Cancer research spans very different kinds of evidence. Laboratory studies in cell lines and animal models reveal mechanisms but often do not translate to patients. Early-phase trials mainly test safety and dosing, while phase 3 randomized trials and their meta-analyses are the usual basis for treatment conclusions. Outcomes also differ in meaning: tumour shrinkage, progression-free survival and overall survival are not interchangeable, and screening studies can be distorted by lead-time and overdiagnosis. When reading a result, check the cancer type and stage studied, the comparison treatment, and which outcome was measured.
Evidence from open-access studies
These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.
| Study / authors | Year | Source label / design | Europe PMC citations | Licence / source |
|---|---|---|---|---|
| Multiscale spatial mapping of cell populations across anatomical sites in healthy human skin and basal cell carcinoma | 2024 | Research article Design not recorded in structured metadata | 61 | cc by PMID 38165934 · DOI · PMC10786309 |
| Functionally distinct cancer-associated fibroblast subpopulations establish a tumor promoting environment in squamous cell carcinoma | 2023 | Research article Design not recorded in structured metadata | 49 | cc by PMID 37669956 · DOI · PMC10480447 |
| Emerging Roles of Hedgehog Signaling in Cancer Immunity | 2023 | Review article Design not recorded in structured metadata | 45 | cc by PMID 36674836 · DOI · PMC9864846 |
| Weakly supervised deep learning for cutaneous squamous and basal cell carcinoma in whole-slide histopathology | 2026 | Research article Design not recorded in structured metadata | 2 | cc by PMID 41841638 · DOI · PMC13093612 |
Multiscale spatial mapping of cell populations across anatomical sites in healthy human skin and basal cell carcinoma [1]
Abstract reading summary — source excerpts
- Opening excerpt
- Our understanding of how human skin cells differ according to anatomical site and tumour formation is limited.
- Closing excerpt
- The resource we have created is publicly available in an interactive format for the research community.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (185 words)
Our understanding of how human skin cells differ according to anatomical site and tumour formation is limited. To address this, we have created a multiscale spatial atlas of healthy skin and basal cell carcinoma (BCC), incorporating in vivo optical coherence tomography, single-cell RNA sequencing, spatial global transcriptional profiling, and in situ sequencing. Computational spatial deconvolution and projection revealed the localisation of distinct cell populations to specific tissue contexts. Although cell populations were conserved between healthy anatomical sites and in BCC, mesenchymal cell populations including fibroblasts and pericytes retained signatures of developmental origin. Spatial profiling and in silico lineage tracing support a hair follicle origin for BCC and demonstrate that cancer-associated fibroblasts are an expansion of a POSTN+ subpopulation associated with hair follicles in healthy skin. RGS5+ pericytes are also expanded in BCC suggesting a role in vascular remodelling. We propose that the identity of mesenchymal cell populations is regulated by signals emanating from adjacent structures and that these signals are repurposed to promote the expansion of skin cancer stroma. The resource we have created is publicly available in an interactive format for the research community.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 38165934 · DOI · PMC10786309
Functionally distinct cancer-associated fibroblast subpopulations establish a tumor promoting environment in squamous cell carcinoma [2]
Abstract reading summary — source excerpts
- Opening excerpt
- Cutaneous squamous cell carcinoma (cSCC) is a serious public health problem due to its high incidence and metastatic potential.
- Closing excerpt
- Our study provides important insights into the potential origin and functionalities of dermal CAFs that will be highly beneficial for the specific targeting of the cSCC microenvironment.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (151 words)
Cutaneous squamous cell carcinoma (cSCC) is a serious public health problem due to its high incidence and metastatic potential. It may progress from actinic keratosis (AK), a precancerous lesion, or the in situ carcinoma, Bowen's disease (BD). During this progression, malignant keratinocytes activate dermal fibroblasts into tumor promoting cancer-associated fibroblasts (CAFs), whose origin and emergence remain largely unknown. Here, we generate and analyze >115,000 single-cell transcriptomes from healthy skin, BD and cSCC of male donors. Our results reveal immunoregulatory and matrix-remodeling CAF subtypes that may derive from pro-inflammatory and mesenchymal fibroblasts, respectively. These CAF subtypes are largely absent in AK and interact with different cell types to establish a pro-tumorigenic microenvironment. These findings are cSCC-specific and could not be recapitulated in basal cell carcinomas. Our study provides important insights into the potential origin and functionalities of dermal CAFs that will be highly beneficial for the specific targeting of the cSCC microenvironment.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 37669956 · DOI · PMC10480447
Emerging Roles of Hedgehog Signaling in Cancer Immunity [3]
Abstract reading summary — source excerpts
- Opening excerpt
- Hedgehog-GLI (HH) signaling plays an essential role in embryogenesis and tissue homeostasis.
- Closing excerpt
- In addition, we discuss the future prospect of therapeutic options combining the HH pathway and immune checkpoint inhibitors.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (195 words)
Hedgehog-GLI (HH) signaling plays an essential role in embryogenesis and tissue homeostasis. Aberrant activation of the pathway through mutations or other mechanisms is involved in the development and progression of numerous types of cancer, including basal cell carcinoma, medulloblastoma, melanoma, breast, prostate, hepatocellular and pancreatic carcinomas. Activation of HH signaling sustains proliferation, suppresses cell death signals, enhances invasion and metastasis, deregulates cellular metabolism and promotes angiogenesis and tumor inflammation. Targeted inhibition of the HH pathway has therefore emerged as an attractive therapeutic strategy for the treatment of a wide range of cancers. Currently, the Smoothened (SMO) receptor and the downstream GLI transcriptional factors have been investigated for the development of targeted drugs. Recent studies have revealed that the HH signaling is also involved in tumor immune evasion and poor responses to cancer immunotherapy. Here we focus on the effects of HH signaling on the major cellular components of the adaptive and innate immune systems, and we present recent discoveries elucidating how the immunosuppressive function of the HH pathway is engaged by cancer cells to prevent immune surveillance. In addition, we discuss the future prospect of therapeutic options combining the HH pathway and immune checkpoint inhibitors.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 36674836 · DOI · PMC9864846
Weakly supervised deep learning for cutaneous squamous and basal cell carcinoma in whole-slide histopathology [4]
Abstract reading summary — source excerpts
- Opening excerpt
- Distinguishing infiltrative basal cell carcinoma (BCC) from poorly differentiated cutaneous squamous cell carcinoma (cSCC) remains a significant histopathological challenge.
- Closing excerpt
- However, reliable deployment across institutions necessitates careful calibration and domain adaptation, and even powerful foundation models such as HistoGPT benefit from targeted fine-tuning to ensure robust performance in dermatopathology.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (357 words)
Distinguishing infiltrative basal cell carcinoma (BCC) from poorly differentiated cutaneous squamous cell carcinoma (cSCC) remains a significant histopathological challenge. Automated deep learning approaches hold promise for improving diagnostic reliability, yet robust external validation is essential. In this study, we developed a weakly supervised deep learning model to classify these diagnostically challenging subtypes and evaluated its generalizability across internal and external cohorts, as well as in comparison to a dermatopathology foundation model (HistoGPT). The model employed a multiple-instance learning framework (CLAM) using the histopathology-specific transformer Phikon for feature extraction from whole-slide images. Slide-level ground-truth diagnoses from the collected images (n = 335, University Hospital Erlangen) were derived from routine clinical practice and re-evaluated by two board-certified dermatopathologists. Performance was assessed on an internal test set of 84 whole-slide images (27 cSCC and 57 BCC) and two external datasets: Queensland cohort (n = 10, curated in-distribution cases) and the COBRA cohort (n = 200, broad, partly out-of-distribution cases). Model discrimination was quantified using ROC curves, while accuracy, sensitivity, and specificity were reported alongside 95% Wilson confidence intervals (CIs). On the internal test set, the model achieved perfect classification [area under the receiver operating characteristic (AUC) = 1.0; 100% accuracy, sensitivity, and specificity]. Similarly, strong performance was observed in the Queensland cohort (AUC = 1.0), although limited by sample size. In the more heterogeneous COBRA cohort, discrimination remained high (AUC = 0.923, 95% CI 0.885-0.961), requiring threshold adjustment to correct for marked calibration shift (balanced accuracy 86.5% at Youden's J). Attention heatmaps highlighted histologically meaningful regions. In zero-shot evaluation on the internal test set, HistoGPT achieved an overall accuracy of 77%, with high class-wise sensitivity for BCC (98%, 95% CI 91-100) but markedly reduced sensitivity for cSCC (33%, 95% CI 19-52). Fine-tuning a task-specific classifier on the HistoGPT backbone substantially improved performance, achieving near-perfect discrimination and 98% balanced accuracy. These findings demonstrate that weakly supervised deep learning enables highly accurate classification of diagnostically challenging BCC and cutaneous squamous cell carcinoma subtypes. However, reliable deployment across institutions necessitates careful calibration and domain adaptation, and even powerful foundation models such as HistoGPT benefit from targeted fine-tuning to ensure robust performance in dermatopathology.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41841638 · DOI · PMC13093612
Key reviews and meta-analyses
The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.
- Research article European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023 [5]
- Research article Understanding the Molecular Genetics of Basal Cell Carcinoma [6]
- Research article Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin: Executive Summary of an American Society for Radiation Oncology Clinical Practice Guideline [7]
- Research article Basal Cell Carcinoma Review [8]
- Research article Non-Melanoma Skin Cancers: Biological and Clinical Features [9]
- Research article Basal Cell Carcinoma: A Comprehensive Review [10]
References
- Ganier C, Mazin P, Herrera-Oropeza G, Du-Harpur X, Blakeley M, Gabriel J, et al.. Multiscale spatial mapping of cell populations across anatomical sites in healthy human skin and basal cell carcinoma. . 2024. PMID 38165934 · DOI · PMC10786309
- Schütz S, Solé-Boldo L, Lucena-Porcel C, Hoffmann J, Brobeil A, Lonsdorf AS, et al.. Functionally distinct cancer-associated fibroblast subpopulations establish a tumor promoting environment in squamous cell carcinoma. . 2023. PMID 37669956 · DOI · PMC10480447
- Giammona A, Crivaro E, Stecca B. Emerging Roles of Hedgehog Signaling in Cancer Immunity. . 2023. PMID 36674836 · DOI · PMC9864846
- Petzold A, Wessely A, Schliep S, Jiang H, Tran M, Koch EA, et al.. Weakly supervised deep learning for cutaneous squamous and basal cell carcinoma in whole-slide histopathology. . 2026. PMID 41841638 · DOI · PMC13093612
- Peris K, Fargnoli MC, Kaufmann R, Arenberger P, Bastholt L, Seguin NB, et al.. European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023. Eur J Cancer. 2023. PMID 37604067 · DOI
- Pellegrini C, Maturo MG, Di Nardo L, Ciciarelli V, Gutiérrez García-Rodrigo C, Fargnoli MC. Understanding the Molecular Genetics of Basal Cell Carcinoma. Int J Mol Sci. 2017. PMID 29165358 · DOI · PMC5713451
- Likhacheva A, Awan M, Barker CA, Bhatnagar A, Bradfield L, Brady MS, et al.. Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin: Executive Summary of an American Society for Radiation Oncology Clinical Practice Guideline. Pract Radiat Oncol. 2020. PMID 31831330 · DOI
- Kim DP, Kus KJB, Ruiz E. Basal Cell Carcinoma Review. Hematol Oncol Clin North Am. 2019. PMID 30497670 · DOI
- Cives M, Mannavola F, Lospalluti L, Sergi MC, Cazzato G, Filoni E, et al.. Non-Melanoma Skin Cancers: Biological and Clinical Features. Int J Mol Sci. 2020. PMID 32751327 · DOI · PMC7432795
- Dika E, Scarfì F, Ferracin M, Broseghini E, Marcelli E, Bortolani B, et al.. Basal Cell Carcinoma: A Comprehensive Review. Int J Mol Sci. 2020. PMID 32759706 · DOI · PMC7432343
About this article
- Sources
- NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
- Verification
- Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
- Review state
- automated source verified; no human expert review has been recorded yet.
- Version
- 1, last updated 2026-10-29.
See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.
Evidence strength
EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.